Jupiter Topco LLC Takes Position in West Pharmaceutical Services, Inc. $WST

Jupiter Topco LLC purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,172 shares of the medical instruments supplier’s stock, valued at approximately $2,934,000.

Several other institutional investors have also recently added to or reduced their stakes in WST. BlackRock Inc. acquired a new stake in West Pharmaceutical Services during the 2nd quarter worth approximately $2,387,990,000. Bank of New York Mellon Corp acquired a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $733,733,000. Generation Investment Management LLP acquired a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $728,168,000. Norges Bank purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth approximately $272,041,000. Finally, Findlay Park Partners LLP purchased a new stake in shares of West Pharmaceutical Services during the second quarter worth approximately $214,196,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $342.88 on Thursday. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $386.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The business has a fifty day moving average of $350.87 and a two-hundred day moving average of $306.04. The company has a market cap of $24.13 billion, a P/E ratio of 43.90, a price-to-earnings-growth ratio of 2.37 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is presently 11.27%.

Analyst Ratings Changes

WST has been the topic of a number of analyst reports. Evercore reiterated an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Morgan Stanley lifted their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Citigroup boosted their price target on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Wolfe Research began coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.